News NICE says no to Genmab cervical cancer therapy Genmab's recently approved therapy for relapsed cervical cancer has been turned down for NHS use in initial NICE guidance.
News BioNTech bigwigs will step down to form new mRNA company The co-founders of mRNA specialist BioNTech – husband and wife team Uğur Şahin and Özlem Türeci – have said they are leaving to set up a new company.
News BMS eyes another celmod filing in myeloma after phase 3 win Bristol Myers Squibb now has positive phase 3 data under its belt for celmod mezigdomide, as it waits for an FDA verdict on lead drug iberdomide.
News Incyte breaks new ground in anal cancer with EU approval Incyte claims EU approval for Zynyz as the first systemic therapy for anal cancer, as J&J gets the nod for wider use of Akeega in prostate cancer.
News Roche's oral SERD flunks phase 3 breast cancer test Roche's recent run of positive study results with breast cancer candidate giredestrant has come to an end with the failure of the persevERA trial.
News Safety concerns prompt Ipsen to pull Tazverik from market Ipsen is voluntarily withdrawing its EZH2 inhibitor Tazverik from sale after a clinical trial suggested a link with secondary blood cancers.
News Iran hackers claim cyberattack at US medtech firm Cyberattack by an Iranian group against Stryker points to a shift in strategy from extortive to destructive assaults, as geopolitical conflicts rise.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
